本文由小咖机器人翻译整理

期刊来源：Ann Intern Med

原文链接：https://doi.org/10.7326/M24-0505

摘要内容如下：

本文总结了2023年以来内科专家在临床上重要的胃肠病学进展。在结直肠癌筛查中，一种新的RNA粪便筛查测试即将出现，以及一项关于在结肠镜筛查中使用人工智能检测更多息肉的益处的新分析。消化道出血的治疗有了新的证据，治疗复发性小肠血管发育不良的新药，消化道肿瘤出血患者有了新的内镜治疗方法。作者介绍了一项由初级保健提供者进行的关于阿米替林治疗肠易激综合征患者的随机试验，并为您带来了关于治疗炎症性肠病和嗜酸性食管炎的新型生物制剂的消息。最后，他们回顾了2篇关于代谢功能障碍相关的脂肪肝疾病的新术语和管理的重要文章。

英文原文如下：

Abstracts

This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for patients with irritable bowel syndrome by primary care providers and bring you news about new biologic agents for inflammatory bowel disease and eosinophilic esophagitis. Finally, they review 2 important articles on new terminology and management of metabolic dysfunction-associated fatty liver disease.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。